Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fractureA double-blind placebo-controlled pilot study in 20 patients
Abstract:Background A catabolic state develops after a hip fracture, with loss of muscle and bone tissue. Growth hormone (GH) treatment has been shown to exert anabolic effects during other catabolic states. We investigated whether GH given postoperatively to elderly hip fracture patients could increase serum insulin-like growth factor-I (IGF-I) and reduce the loss of lean body mass and bone mineral content (BMC) without considerable side effects.Patients and methods We randomized 20 patients operated on for a hip frac… Show more
“…Various authors documented the therapeutic use of GH and IGFs on acceleration of fracture healing mostly in animal models with partly conflicting and controversial results [22][23][24][25][26]. In the few clinical trials heading systemic administration of GH in patients, the hormone failed to improve rate and quality of fracture healing [31] while it increased bone mineral content [27] and rate of return to the pre-fracture living situation in the elderly with hip fractures [28]. Even less information is available on therapeutic use of GH/ IGF system in failed fracture healing.…”
“…Various authors documented the therapeutic use of GH and IGFs on acceleration of fracture healing mostly in animal models with partly conflicting and controversial results [22][23][24][25][26]. In the few clinical trials heading systemic administration of GH in patients, the hormone failed to improve rate and quality of fracture healing [31] while it increased bone mineral content [27] and rate of return to the pre-fracture living situation in the elderly with hip fractures [28]. Even less information is available on therapeutic use of GH/ IGF system in failed fracture healing.…”
“…A small double-blind study reported a lean body-preserving effect of short-term GH treatment (Hedström et al 2004) (Table) and another double-blind short-term GH therapy study showed a faster return to prefracture living (van der Lely et al 2000) (Table). This was in contrast to a recent 6 month-study with oral GH secretagogue given to hip fracture patients who reported no functional improvement from this treatment (Bach et al 2004) (Table).…”
Section: Recombinant Human Growth Hormone and Igf-imentioning
confidence: 99%
“…This was in contrast to a recent 6 month-study with oral GH secretagogue given to hip fracture patients who reported no functional improvement from this treatment (Bach et al 2004) (Table). Moreover, there have been reports of serious side effects of GH treatment in acute critically ill patients (Takala et al 1999), but not in hip fracture patients when therapy was started 3-4 days postoperatively (Yeo et al 2003, Hedström et al 2004. Daily infusions of recombinant IGF-I/ IGFBP-3 complex for 2 months in hip fracture Table).…”
Section: Recombinant Human Growth Hormone and Igf-imentioning
“…Recent human studies on the effects of GH on patients sustaining fractures place emphasis on the functional recovery of patients; therefore, most of the published data include indirect evidence of fracture healing. The intended benefit of GH administration in human fracture patients in most of the available studies has been to determine the systemic effect against the catabolic state that these patients enter after their injury/operation [133,[136][137][138][139][140].…”
The optimal dose and method of administration is still to be determined, and the safety profile of this novel use of GH needs to be investigated prior to establishing its widespread use as a fracture-healing agent.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.